Related Experiment Videos
Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies
William M Gallagher1, Orla E Bergin, Mairin Rafferty
1Department of Pharmacology, University College Dublin, Ireland. william.gallagher@ucd.ie
Carcinogenesis
|June 17, 2005
Summary
Melanoma progression involves DNA hypermethylation of key genes, including TSPY. Treatment with 2'-deoxy-5-azacytidine (DAC) reversed this, suppressed tumor growth, and re-expressed TSPY in melanoma models.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Melanoma incidence is rising, with advanced stages showing poor response to chemotherapy.
- Identifying molecular drivers of melanoma progression is crucial for developing new therapies.
Purpose of the Study:
- To identify molecular determinants of melanoma progression using gene expression profiling.
- To investigate the role of DNA methylation in melanoma progression and therapeutic potential.
Main Methods:
- Utilized DNA microarray and TaqMan Low Density Array (LDA) for gene expression profiling in isogenic human melanoma cell lines.
- Examined TSPY gene methylation and the effect of DNA methyltransferase inhibitor 2 -deoxy-5-azacytidine (DAC) on gene expression and tumor growth.
- Assessed melanoma xenograft growth in mice following systemic DAC treatment.
Main Results:
- Identified 66 differentially expressed genes associated with melanoma progression.
- Discovered TSPY gene down-regulation and hypermethylation in aggressive melanoma cell lines and patient samples.
- DAC treatment restored TSPY expression, suppressed tumor cell growth in vitro, and attenuated melanoma xenograft growth in vivo.
Conclusions:
- Melanoma progression is associated with DNA hypermethylation targeting multiple genes, including TSPY.
- TSPY is a novel marker for melanoma progression and a potential therapeutic target.
- DAC demonstrates therapeutic potential for melanoma by reversing epigenetic silencing and inhibiting tumor growth.